NAT10 drives a suppressive Treg program in lung tumors
A new study in murine lung tumors points to N-acetyltransferase 10, or NAT10, as an unexpected regulator of immune suppression inside the tumor microenvironment. The work centers on Tregs, the regulatory T cells that normally restrain immune activation but can be co-opted by tumors to blunt antitumor immunity. In this setting, the therapeutic problem is straightforward: immune checkpoint blockade can unleash effector T cells, yet the same treatment can leave a suppressive Treg compartment intact enough to keep the tumor protected.
In human non–small cell lung cancer, NAT10-modified RNA accumulated particularly in NAT10+FOXP3+ Tregs. That observation provided the first clue that NAT10 is not merely present in tumor-infiltrating regulatory cells; it may help define their functional state. The murine experiments then moved from association to mechanism, asking whether NAT10 helps preserve the Treg program that limits response to anti–PD-1 therapy.
Loss of NAT10 shifts the balance away from suppressive Tregs
Genetic ablation of Nat10 in tumor-infiltrating Tregs reduced the PD-1+ Treg/CD8+ T cell ratio. Pharmacological inhibition of NAT10 produced a similar effect. In practical immunology terms, fewer PD-1-expressing Tregs relative to cytotoxic CD8 cells means less dominance of the suppressive arm and more room for effector immunity to operate inside the tumor.
This was not just a surface-marker change. NAT10 inhibition was accompanied by an increase in IFN-γ+ Tregs, a reduction in Treg suppressive activity, and inhibition of tumor progression. The phenotype points to Treg fragility rather than simple disappearance. A Treg that begins to produce interferon-gamma is no longer behaving like a fully stable suppressor, and that functional drift can matter as much as cell number when tumors depend on immune restraint for survival.
One sentence captures the therapeutic pivot: blocking NAT10 weakened the tumor’s regulatory shield.
Chromatin remodeling, not RNA modification, appears to be the key
The mechanistic core of the paper is especially notable because NAT10 acted independently of its RNA-modifying function. Instead of working through the canonical enzymatic pathway alone, NAT10 directly interacted with FOXP3 and chromatin. That interaction altered local 3D chromatin contacts, which in turn shaped Treg-associated gene expression.
The chromatin work converged on super-enhancer biology. Treg-specific super-enhancers were linked to signature genes including Tnfrsf18 (GITR), Tnfrsf4 (OX40), Cxcr4, Tnfrsf9 (4-1BB), Pdcd1 (PD-1), and Icos. At the Cxcr4, Pdcd1, and Tnfrsf9 loci, NAT10 and FOXP3 occupancy aligned with active chromatin features, including H3K27ac enrichment and accessible chromatin tracks. In the lung tumor microenvironment, that type of regulatory wiring can support Treg recruitment, persistence, and suppressive fitness.
The most direct bedside implication is not that NAT10 is a universal immune target. It is that a tumor can use a chromatin-associated factor to maintain a specialized suppressive cell state, and that cell state may be more druggable than previously assumed.
FOXP3-linked gene control helped sustain Treg infiltration and activity
The figure data reinforce the idea that NAT10 helps establish a transcriptional program rather than simply marking activated Tregs. Chromatin looping analysis showed that NAT10 and FOXP3 cobound regions associated with Treg super-enhancers, and the Cxcr4-containing locus displayed altered contact patterns when Nat10 was absent. FOXP3 enrichment at the promoters of Cxcr4, Pdcd1, and Tnfrsf9 was also demonstrated in tumor-infiltrating Tregs.
That matters because CXCR4 can support positioning and trafficking, while PD-1 and 4-1BB are embedded in the activation state of tumor-associated Tregs. Together, these signals help explain why NAT10-deficient Tregs were less able to accumulate and maintain a suppressive phenotype within lung tumors. The paper’s adoptive transfer experiment also supports this point: when WT or Nat10-deficient Tregs were transferred into CD45.1 mice, the Nat10-deficient cells were less effective at establishing a tumor-infiltrating regulatory compartment.
Combined NAT10 inhibition and anti–PD-1 improved tumor control
The combination result is the most clinically relevant part of the study. Anti–PD-1 antibodies paired with a NAT10 inhibitor further impaired Treg-mediated immunosuppression and produced enhanced tumor control compared with either approach alone.
That pairing makes biological sense. Anti–PD-1 therapy aims to revive exhausted or restrained antitumor lymphocytes, but tumors often counterbalance that effect by preserving suppressive Tregs. If NAT10 inhibition weakens Treg fitness at the same time checkpoint blockade lifts the brakes on CD8 T cells, the immune system receives two coordinated signals: one to attack and one to stop protecting the tumor.
The result does not yet define a clinical strategy for patients with lung cancer, and the study is confined to murine tumors with supporting human tissue observations. Even so, it identifies a specific vulnerability in the tumor-infiltrating Treg program and gives a mechanistic explanation for why checkpoint response can remain incomplete. NAT10 sits at the intersection of FOXP3-dependent transcription, chromatin architecture, and Treg suppressive function, making it a plausible co-target for future immunotherapy combinations.
The remaining challenge is translational, not conceptual. A NAT10 inhibitor will need to prove that it can reshape intratumoral immunity without disrupting beneficial immune regulation elsewhere, and that question will require careful testing beyond the murine lung tumor setting.